北京中医药大学学报2024，Vol.47Issue(5)：709-720,12.DOI:10.3969/j.issn.1006-2157.2024.05.016
含砷中药复方治疗的高危骨髓增生异常综合征患者的生存特征分析
Survival characteristics of patients with high-risk myelodysplastic syndromes treated with an arsenic-containing herbal combination
摘要
Abstract
Objective To investigate the clinical characteristics of survival in patients with high-risk myelodysplastic syndromes(HR-MDS)and provide a reference for the clinical prognosis of patients with HR-MDS.Methods General data,blood routine test,bone marrow smear with histopathology,cytogenetics,and other clinical data of 200 patients diagnosed with HR-MDS at Xiyuan Hospital of China Academy of Chinese Medical Sciences,during the period of January 2016-September 2022,were retrospectively analyzed.The included patients were categorized into the arsenic-containing herbal combination combined with demethylating agents(HMAs)treatment group and the arsenic-containing Chinese medicine compound combined with androgen treatment group.The influence of clinical indices on the survival characteristics of each group was analyzed.Results Comparison of the impact of clinical indicators on survival in 200 patients with HR-MDS who were treated with arsenic-containing herbal compounds in combination with HMAs or androgens showed that high-risk vs.very high-risk(P=0.018),hemoglobin(Hb)<80 g/L vs.Hb≥80 g/L(P=0.035),platelet(PLT)counts<50×109 L-1 vs.PLT counts≥50×109 L-1(P<0.001),and the difference in median progression-free survival(PFS)time between myelodysplastic syndromes converted to leukemia(MDS-AML)and non-MDS-AML(P=0.003)were statistically significant.Comparison of survival effects of clinical indicators in 68 patients with HR-MDS who were treated with arsenic-containing Chinese medicine compound combined with HMAs showed that the difference in median PFS between PLT count<50×109 L-1 and PLT count≥50×109 L-1(P<0.001)and the difference in median PFS between<5 and≥5 courses of chemotherapy(P=0.018)were statistically significant.Comparison of survival effects of clinical indicators in 132 patients with HR-MDS who were treated with arsenic-containing Chinese medicine compound combined with androgens showed that Hb<80 g/L and Hg≥80 g/L(P=0.028),PLT count<50×109 L-1 and PLT count≥50×109 L-1(P=0.002),and the mean differences in PFS between MDS-AML and non-MDS-AML(P=0.024)were statistically significant.Conclusion The clinical characteristics of long-surviving patients treated with arsenic-containing herbal combination in combination with HMAs included PLT counts≥50×109 L-1 and≥5 courses of chemotherapy.The clinical characteristics of long-surviving patients treated with arsenic-containing herbal combination in combination with androgens included Hg≥80 g/L,PLT count≥50×109 L-1,and non-MDS-AML.关键词
高危骨髓增生异常综合征/血液疾病/生存分析/含砷中药复方/雄激素/总生存期/无进展生存期Key words
high-risk myelodysplastic syndrome/blood diseases/survival analysis/arsenic-containing herbal combination/androgen/overall survival/progression-free survival分类
医药卫生引用本文复制引用
靳楠,毛悦,吕妍,陈卓,王德秀,刘为易,刘驰,唐旭东..含砷中药复方治疗的高危骨髓增生异常综合征患者的生存特征分析[J].北京中医药大学学报,2024,47(5):709-720,12.基金项目
国家自然科学基金面上项目(No.82074258,No.82274502) （No.82074258,No.82274502）
北京市第二批研究型病房示范建设项目(No.BCRW202108) （No.BCRW202108）
中国中医科学院科技创新工程重大攻关项目(No.CI2021A01701) National Natural Science Foundation of China(Nos.82074258 and 82274502) （No.CI2021A01701）
